CNS Drugs

, Volume 15, Issue 7, pp 505–514

Vaccines Against Nicotine

How Effective are They Likely to be in Preventing Smoking?
Leading Article

Abstract

Cigarette smoking is the most preventable cause of death in industrialised countries. 30% of all deaths in smokers in the 35 to 69 years age range are attributed to chronic cigarette smoking; smokers dying in this age cohort lose an average of 23 years of life. Public he1alth campaigns have attempted to reduce initiation of smoking in adolescents and to foster quitting in dependent smokers. The prevalence of smoking has declined in the US to 25% of the population, but this figure has held constant for the last decade.

Vaccines against nicotine are a novel concept in the field of smoking cessation research and have not yet reached the stage of clinical testing. Vaccines could reduce smoking behaviour in 3 groups of smokers: (i) current smokers attempting to quit; (ii) former smokers wanting to avoid the possibility of relapse; and (iii) adolescent smokers before they become confirmed smokers. The rationale behind the approach is that nicotine is the pharmacological agent controlling the rate of cigarette smoking, and reducing its rate and extent of uptake into the brain may have therapeutic benefits.

References

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  2. 2.
    Peto R, Lopez AD, Boreham J, et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992 May 23; 339(8804): 1268–78PubMedCrossRefGoogle Scholar
  3. 3.
    United States Department of Health and Human Services. The health benefits of smoking cessation. Washington, DC: United States Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 1990. DHHS Publication No. (CDC) 90-8416Google Scholar
  4. 4.
    United States Department of Health and Human Services. The health consequences of smoking. Nicotine addiction: a report of the Surgeon General. Washington, DC: United States Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 1988. DHHS Publication No. (CDC) 88-8406Google Scholar
  5. 5.
    Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85: 5274–8PubMedCrossRefGoogle Scholar
  6. 6.
    Acques E, Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 1992; 58(5): 1620–5CrossRefGoogle Scholar
  7. 7.
    Goldberg SR, Spealman RD, Goldberg DM. Persistent behavior at high rates maintained by intravenous nicotine administration. Science 1981; 214: 573–5PubMedCrossRefGoogle Scholar
  8. 8.
    Henningfield JE, Goldberg SR. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 1983; 19: 989–92PubMedCrossRefGoogle Scholar
  9. 9.
    Henningfield JE, Miyasato K, Jasinki DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 1985; 34: 1–12Google Scholar
  10. 10.
    Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1983; 61: 743–50Google Scholar
  11. 11.
    Benowitz NL. Pharmacological aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988; 319: 1318–30PubMedCrossRefGoogle Scholar
  12. 12.
    Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498–529PubMedCrossRefGoogle Scholar
  13. 13.
    Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 1973; 20: 119–29PubMedCrossRefGoogle Scholar
  14. 14.
    Gorelick DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998; 42: 995–7PubMedCrossRefGoogle Scholar
  15. 15.
    De Wit H. Priming effects with drugs and other reinforcers. Exp Clin Psychopharmacol 1996; 4: 5–10CrossRefGoogle Scholar
  16. 16.
    Chornock WM, Stitzer ML, Gross J, et al. Experimental model of smoking re-exposure: effects on relapse. Psychopharmacology (Berl) 1992; 108: 495–500CrossRefGoogle Scholar
  17. 17.
    Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996; 93(24): 14065–69PubMedCrossRefGoogle Scholar
  18. 18.
    Fowler JS, Volkow ND, Wang GJ, et al. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J Addict Dis 1998; 17(1): 23–34PubMedCrossRefGoogle Scholar
  19. 19.
    Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care 1999; 26(3): 653–9PubMedCrossRefGoogle Scholar
  20. 20.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340(9): 685–91PubMedCrossRefGoogle Scholar
  21. 21.
    Covey LS, Sullivan MA, Johnston JA, et al. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 2000; 59(1): 17–31PubMedCrossRefGoogle Scholar
  22. 22.
    Lutwick LI. Unconventional vaccine targets: immunization for pregnancy, peptic ulcer, gastric cancer, cocaine abuse, and atherosclerosis. New Vaccines and New Vaccine Technology 1999; 13(1): 245–64Google Scholar
  23. 23.
    Bonese K, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 1974; 252: 708–10PubMedCrossRefGoogle Scholar
  24. 24.
    Bagasra O, Forman LJ, Howeedy A, et al. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology 1992; 23(3): 173–9PubMedCrossRefGoogle Scholar
  25. 25.
    Carrera MRA, Ashley JA, Parsons LH, et al. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995; 378: 727–30PubMedCrossRefGoogle Scholar
  26. 26.
    Ettinger RH, Ettinger WF, Harless WE, et al. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 1997; 58: 215–20PubMedCrossRefGoogle Scholar
  27. 27.
    Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2(10): 1129–32PubMedCrossRefGoogle Scholar
  28. 28.
    Fox BS. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 1997; 48: 153–8PubMedCrossRefGoogle Scholar
  29. 29.
    Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anti-cocaine antibodies and cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000; 148: 251–62CrossRefGoogle Scholar
  30. 30.
    Hieda Y, Keyler DE, VanDeVoort JT, et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997; 283(3): 1076–81PubMedGoogle Scholar
  31. 31.
    Hieda Y, Keyler DE, VanDeVoort JT, et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl) 1999; 143(2): 150–7CrossRefGoogle Scholar
  32. 32.
    Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and accentuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65(1): 191–8PubMedCrossRefGoogle Scholar
  33. 33.
    O’Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 1997; 49: 1–10Google Scholar
  34. 34.
    Jennings R, Simms JK, Heath AW. Adjuvants and delivery systems for viral vaccines: mechanisms and potential. Dev Biol Stand 1998; 28: 19–28Google Scholar
  35. 35.
    Zevin S, Gourlay SG, Benowitz NL. Clinical pharmacology of nicotine. Clin Dermatol 1998, 16: 557–64PubMedCrossRefGoogle Scholar
  36. 36.
    Rose JE, Behm FM, Westman EC, et al. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implication for addiction. Drug Alcohol Depend 1999; 56: 99–107PubMedCrossRefGoogle Scholar
  37. 37.
    Rand MJ. Neuropharmacological effects of nicotine in relation to cholinergic mechanisms. In: Nordberg A, Fuxe K, Holmstedt B, et al., editors. Progress in brain research. Amsterdam: Elsevier Science Publishers, 1989; 79: 3–11Google Scholar
  38. 38.
    Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993; 33(1): 23–9PubMedCrossRefGoogle Scholar
  39. 39.
    Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997; 62(4): 453–63PubMedCrossRefGoogle Scholar
  40. 40.
    Janoff EN, Hardy WD, Smith PD, et al. Humoral recall responses in HIV infection: levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991; 147(7): 2130–5PubMedGoogle Scholar
  41. 41.
    Weiss PJ, Wallace MR, Oldfield EC, et al. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995; 171: 1217–22PubMedCrossRefGoogle Scholar
  42. 42.
    Hardin JS, Wessinger WD, Proksch JW, et al. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 1998; 285(3): 1113–22PubMedGoogle Scholar
  43. 43.
    Benowitz NL, Jacob P III. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984; 35: 499–504PubMedCrossRefGoogle Scholar
  44. 44.
    Rosa M, Pacifici R, Altieri I, et al. How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake. Clin Pharmacol Ther 1992; 52(3): 324–9PubMedCrossRefGoogle Scholar
  45. 45.
    Jones RT. The pharmacology of cocaine smoking in humans. In: Chiang CN, Hawks RL, editors. Research findings on smoking of abused substances. Washington, DC: Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration 1990; National Institute on Drug Abuse Research Monograph 99: 30–41Google Scholar
  46. 46.
    Hieda Y, Keyler DE, Ennifar S, et al. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22(10): 809–19PubMedCrossRefGoogle Scholar
  47. 47.
    Killian A, Bonese K, Rothberg RM, et al. Effects of passive immunization against morphine on heroin self-administration. Pharmacol Biochem Behav 1978; 9(3): 347–51PubMedCrossRefGoogle Scholar
  48. 48.
    Benowitz NL, Hall SM, Herning RI, et al. Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med 1983; 309: 139–42PubMedCrossRefGoogle Scholar
  49. 49.
    Colburn WA. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab Rev 1980; 11: 223–62PubMedCrossRefGoogle Scholar
  50. 50.
    Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly change phencyclidine concentration in brain and other tissues in rats. J Pharmacol Exp Ther 1996; 278(2): 717–72PubMedGoogle Scholar
  51. 51.
    Keyler DE, Hieda Y, St Peter J, et al. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999; 1: 241–9PubMedCrossRefGoogle Scholar
  52. 52.
    Benowitz NL, Kuyt F, Jacob P. Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 1982; 32, 758–64PubMedCrossRefGoogle Scholar
  53. 53.
    Kosten TR, Rosen M, Bond J, et al. Human cocaine vaccine: safety and immunogenicity. Vaccine. In pressGoogle Scholar
  54. 54.
    Centers for Disease Control. Cigarette smoking among adults: United States 1997. MMWR Morb Mortal Wkly Rep 1999; 48: 993–6Google Scholar
  55. 55.
    Centers for Disease Control. Cigarette smoking among adults: United States 1995. MMWR Morb Mortal Wkly Rep 1997; 46: 1217–20Google Scholar
  56. 56.
    Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol 1998; 148: 249–58PubMedCrossRefGoogle Scholar
  57. 57.
    United States Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General. Washington, DC: United States Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 1994Google Scholar
  58. 58.
    Giovino GA, Henningfield JE, Tomar SL, et al. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995; 17: 48–65PubMedGoogle Scholar
  59. 59.
    Hu T, Lin Z, Keeler TE. Teenage smoking, attempts to quit, and school performance. Am J Public Health 1998; 88: 940–3PubMedCrossRefGoogle Scholar
  60. 60.
    Hurt RD, Croghan GA, Beede SD, et al. Nicotine patch therapy in 101 adolescent smokers. Arch Pediatr Adolesc Med 2000; 154: 31–7PubMedGoogle Scholar
  61. 61.
    Pierce JP, Fiore M, Novotny TE, et al. Trends in cigarette smoking in the United States: projections to the year 2000. JAMA 1989; 261: 61–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Division of Treatment Research and DevelopmentNational Institute on Drug AbuseBethesdaUSA

Personalised recommendations